Fetal Calf Serum (FCS) is the blood fraction remaining after the natural coagulation of blood, followed by centrifugation to remove any remaining red blood cells. The global Fetal Calf Serum (FCS) market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Fetal Calf Serum (FCS) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Fetal Calf Serum (FCS) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: Thermo Fisher GE Healthcare Sigma-Aldrich Merck Moregate BioTech Gemini Atlanta Biologicals Tissue Culture Biologicals Bovogen Biowest Internegocios RMBIO Biological Industries PAN-Biotech VWR Corning Segment by Regions North America Europe China Japan Segment by Type North America-sourced South America-sourced Australia-sourced Others Segment by Application Research & Development Commercial Production
Table of Contents Executive Summary 1 Fetal Calf Serum (FCS) Market Overview 1.1 Product Overview and Scope of Fetal Calf Serum (FCS) 1.2 Fetal Calf Serum (FCS) Segment by Type 1.2.1 Global Fetal Calf Serum (FCS) Production Growth Rate Comparison by Type (2014-2025) 1.2.2 North America-sourced 1.2.3 South America-sourced 1.2.4 Australia-sourced